In the BioHarmony Drug Report Database
Ponatinib
Iclusig (ponatinib) is a small molecule pharmaceutical. Ponatinib was first approved as Iclusig on 2012-12-14. It is used to treat myeloid leukemia in the USA. It has been approved in Europe to treat lymphoid leukemia and myeloid leukemia. The pharmaceutical is active against tyrosine-protein kinase ABL1. In addition, it is known to target cyclin-dependent kinase 19, proto-oncogene tyrosine-protein kinase receptor Ret, cyclin-dependent kinase 8, receptor-interacting serine/threonine-protein kinase 3, receptor-interacting serine/threonine-protein kinase 2, and receptor-interacting serine/threonine-protein kinase 1. Iclusig’s patents are valid until 2033-12-12 (FDA).
Trade Name
|
Iclusig |
|---|---|
Common Name
|
ponatinib |
ChEMBL ID
|
CHEMBL1171837 |
Indication
|
lymphoid leukemia, myeloid leukemia |
Drug Class
|
Tyrosine kinase inhibitors |
Image (chem structure or protein)